TY - JOUR
T1 - Characterisation and prognosis of undiagnosed chronic obstructive pulmonary disease patients at their first hospitalisation
AU - and the PAC-COPD Study Group
AU - Balcells, Eva
AU - Gimeno-Santos, Elena
AU - de Batlle, Jordi
AU - Ramon, Maria Antonia
AU - Rodríguez, Esther
AU - Benet, Marta
AU - Farrero, Eva
AU - Ferrer, Antoni
AU - Guerra, Stefano
AU - Ferrer, Jaume
AU - Sauleda, Jaume
AU - Barberà, Joan A.
AU - Agustí, Álvar G.
AU - Rodriguez-Roisin, Robert
AU - Gea, Joaquim
AU - Antó, Josep M.
AU - Garcia-Aymerich, Judith
AU - Serra, Ignasi
AU - Donaire-Gonzalez, David
AU - Gayete, ADavidngel
AU - Orozco-Levi, Mauricio
AU - Vollmer, Ivan
AU - Barberá, Joan Albert
AU - Gomez, Federico P.
AU - Pare, Carles
AU - Roca, Josep
AU - Freixa, Xavier
AU - Rodriguez, Diego A.
AU - Portillo, Karina
AU - Andreu, Jordi
AU - Pallissa, Esther
AU - Rodriguez, Esther
AU - Casan, Pere
AU - Guell, Rosa
AU - Gimenez, Ana
AU - Monso, Eduard
AU - Marin, Alicia
AU - Morera, Josep
AU - Escarrabill, Joan
AU - Togores, Bernat
AU - Gáldiz, Juan Bautista
AU - López, Lórena
AU - Belda, José
N1 - Funding Information:
Authors wish to thank the Conjunto Mínimo Básico de Datos de Altas Hospitalarias (CMBDAH) from Catalunya, Euskadi and Illes Balears for providing the information on hospitalisation data. The PAC-COPD Study is funded by grants from Fondo de Investigación Sanitaria (FIS PI020541), Ministry of Health, Spain; Agència d’Avaluació de Tecnologia i Recerca Mèdiques (AATRM 035/20/02), Catalonia Government; Spanish Society of Pneumology and Thoracic Surgery (SEPAR 2002/137); Catalan Foundation of Pneumology (FUCAP 2003 Beca Marià Ravà); Red RESPIRA (RTIC C03/11); Red RCESP (RTIC C03/09); Fondo de Investigación Sanitaria (PI052486); Fondo de Investigación Sanitaria (PI052302); Fondo de Investigación Sanitaria (PI060684); Fundació La Marató de TV3 (num. 041110); and Novartis Farmacèutica, Spain. CIBERESP and CIBERES are funded by the Instituto de Salud Carlos III, Ministry of Health, Spain. No involvement of funding sources in the study design, the collection, analysis, and interpretation of data, the writing of the report, or in the decision to submit the article for publication. Researchers are independent from funders.
Publisher Copyright:
© Balcells et al.; licensee BioMed Central.
PY - 2015/1/17
Y1 - 2015/1/17
N2 - Under-diagnosis of COPD is an important unmet medical need. We investigated the characteristics and prognosis of hospitalised patients with undiagnosed COPD. Methods: The PAC-COPD cohort included 342 COPD patients hospitalised for the first time for an exacerbation of COPD (2004-2006). Patients were extensively characterised using sociodemographic, clinical and functional variables, and the cohort was followed-up through 2008. We defined "undiagnosed COPD" by the absence of any self-reported respiratory disease and regular use of any pharmacological respiratory treatment. Results: Undiagnosed COPD was present in 34% of patients. They were younger (mean age 66 vs. 68 years, p = 0.03), reported fewer symptoms (mMRC dyspnoea score, 2.1 vs. 2.6, p < 0.01), and had a better health status (SGRQ total score, 29 vs. 40, p < 0.01), milder airflow limitation (FEV1% ref., 59% vs. 49%, p < 0.01), and fewer comorbidities (two or more, 40% vs. 56%, p < 0.01) when compared with patients with an established COPD diagnosis. Three months after hospital discharge, 16% of the undiagnosed COPD patients had stopped smoking (vs. 5%, p = 0.019). During follow-up, annual hospitalisation rates were lower in undiagnosed COPD patients (0.14 vs. 0.25, p < 0.01); however, this difference disappeared after adjustment for severity. Mortality was similar in both groups. Conclusions: Undiagnosed COPD patients have less severe disease and lower risk of re-hospitalisation when compared with hospitalised patients with known COPD.
AB - Under-diagnosis of COPD is an important unmet medical need. We investigated the characteristics and prognosis of hospitalised patients with undiagnosed COPD. Methods: The PAC-COPD cohort included 342 COPD patients hospitalised for the first time for an exacerbation of COPD (2004-2006). Patients were extensively characterised using sociodemographic, clinical and functional variables, and the cohort was followed-up through 2008. We defined "undiagnosed COPD" by the absence of any self-reported respiratory disease and regular use of any pharmacological respiratory treatment. Results: Undiagnosed COPD was present in 34% of patients. They were younger (mean age 66 vs. 68 years, p = 0.03), reported fewer symptoms (mMRC dyspnoea score, 2.1 vs. 2.6, p < 0.01), and had a better health status (SGRQ total score, 29 vs. 40, p < 0.01), milder airflow limitation (FEV1% ref., 59% vs. 49%, p < 0.01), and fewer comorbidities (two or more, 40% vs. 56%, p < 0.01) when compared with patients with an established COPD diagnosis. Three months after hospital discharge, 16% of the undiagnosed COPD patients had stopped smoking (vs. 5%, p = 0.019). During follow-up, annual hospitalisation rates were lower in undiagnosed COPD patients (0.14 vs. 0.25, p < 0.01); however, this difference disappeared after adjustment for severity. Mortality was similar in both groups. Conclusions: Undiagnosed COPD patients have less severe disease and lower risk of re-hospitalisation when compared with hospitalised patients with known COPD.
KW - Chronic obstructive
KW - Cohort studies
KW - Epidemiology
KW - Health services
KW - Hospitalisation
KW - Pulmonary disease
UR - http://www.scopus.com/inward/record.url?scp=84925234718&partnerID=8YFLogxK
U2 - 10.1186/1471-2466-15-4
DO - 10.1186/1471-2466-15-4
M3 - Article
C2 - 25595204
AN - SCOPUS:84925234718
SN - 1471-2466
VL - 15
JO - BMC Pulmonary Medicine
JF - BMC Pulmonary Medicine
IS - 1
M1 - 4
ER -